Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health

Angiology

Volumn 55, Issue 3, 2004, Pages 233-242

  Hirsch, Alan T ^a   Gloviczki, Peter ^b   Drooz, Alain ^c   Lovell, Marge ^d   Creager, Mark A ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c Vasc and Interventional Associates   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; ORGANIZATION AND MANAGEMENT; PERIPHERAL VASCULAR DISEASE; UNITED STATES;

HEALTH EDUCATION; HEALTH PROMOTION; HUMANS; PERIPHERAL VASCULAR DISEASES; UNITED STATES;

EID: 2942648512     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970405500301     Document Type: Article

References (38)

1. Criqui MH, Fronek A, Barrett-Connor E, et al: The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510–515, 1985.
2. Meijer WT, Hoes AW, Rutgers D, et al: Peripheral arterial disease in the elderly. The Rotterdam Study. Arterioscler Thromb Vasc Biol 18: 185–192, 1998.
3. Fowkes FG, Housley E, Cawood EH, et al, Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20: 384–392, 1991.
4. Leng GC, Lee AJ, Fowkes FG, et al: Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25: 1172–1181, 1996.
5. Kornitzer M, Dramaix M, Sobolski J, et al: Ankle/arm pressure index in asymptomatic middle-aged males: An independent predictor of ten-year coronary heart disease mortality. Angiology 46: 211–219, 1995.
6. Zheng ZJ, Sharrett AR, Chambless LE, et al: Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131: 115–125, 1997.
7. Newman AB, Sutton-Tyrrell K, Vogt MT, et al: Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 270: 487–489, 1993.
8. Criqui MH, Langer RD, Fronek A, et al: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381–386, 1992.
9. Smith GD, Shipley MJ, Rose G: Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 82: 1925–1931, 1990.
10. Vogt MT, Cauley JA, Newman AB: Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270: 465–469, 1993.
11. Breek JC, Hamming JF, De Vries J, et al: The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent, claudication. J Vasc Surg 36: 94–99, 2002.
12. Treat-Jacobson DT, Halverson SL, Ratchford A, et al: A patient-derived perspective of health-related quality-of-life in peripheral arterial disease. J Nurs Scholarsh 34: 55–60, 2002.
13. Khaira HS, Hanger R, Shearman CP: Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 11: 65–69, 1996.
14. Vogt MT, Cauley JA, Kuller LH, et al: Functional status and mobility among elderly women with lower extremity arterial disease: The Study of Osteoporotic Fractures. J Am Geriatr Soc 42: 923–929, 1994.
15. Barletta G, Perna S, Sabba C, et al: Quality of life in patients with intermittent claudication: Relationship with laboratory exercise performance. Vasc Med 1: 3–7, 1996.
16. Pell JP, for the Scottish Vascular Audit Group: Impact of intermittent claudication on quality of life. Eur J Vasc Endovasc Surg 9: 469–472, 1995.
17. Ponte E, Cattinelli S: Quality of life in a group of patients with intermittent claudication. Angiology 47: 247–251, 1996.
18. McDermott MM, Mehta S, Greenland P: Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 159: 387–392, 1999.
19. McDermott MM, Mehta S, Liu K, et al: Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med 14: 173–181, 1999.
20. McDermott MM, Fried L, Simonsick E, et al: Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: The Women's Health and Aging Study. Circulation 101: 1007–1012, 2000.
21. McDermott MM, Greenland P, Liu K, et al: Leg symptoms in peripheral arterial disease: Associated clinical characteristics and functional impairment. JAMA 286: 1599–1606, 2001.
22. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31(1 pt 2):S1-S296, 2000.
23. Belch JJF, Topol EJ, Agnelli G, et al: Critical issues in peripheral arterial disease detection and management: A call to action. Arch Int Med 163: 884–892, 2003.
24. Hirsch AT, Halverson SL, Treat-Jacobson D, et al: The Minnesota Regional Peripheral Arterial Disease Screening Program: Toward a definition of community standards of care. Vasc Med 6: 87–96, 2001.
25. Hirsch AT, Criqui MH, Treat-Jacobson D, et al: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317–1324, 2001.
26. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344: 1608–1621, 2001.
27. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339, 1996.
28. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Errata, N Engl J Med 342: 748, 1376, 2000].
29. N Engl J Med 342: 145–153, 2000.
30. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7–22, 2002.
31. Burt VL, Cutler JA, Higgins M, et al: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991. Hypertension 26: 60–69, 1995.
32. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560–2571, 2003.
33. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497, 2001.
34. Pieper RM, Arnett DK, McGovern PG, et al: Trends in cholesterol knowledge and screening and hypertension awareness and treatment, 1980–1992. The Minnesota Heart Survey. Ach Intern Med 157: 2326–2332, 1997.
35. Farquhar JW, Fortmann SP, Flora JA, et al: Effects of communitywide education on cardiovascular disease risk factors. The Stanford Five-City Project. JAMA 264: 359–365, 1990.
36. Frank E, Winkleby MA, Fortmann SP, et al: Improved cholesterol-related knowledge and behavior and plasma cholesterol levels in adults during the 1980s. JAMA 268: 1566–1572, 1992.
37. Fortmann SP, Flora JA, Winkleby MA, et al: Community intervention trials: Reflections on the Stanford Five City Project experience. Am J Epidemiol 142: 576–586, 1995.
38. NHLBI Workshop on peripheral arterial disease (PAD): Developing A Public Awareness Campaign Meeting Summary. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Bethesda, MD, 2003.